Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20052432 | 0.91 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL10144173 | 0.90 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL15462624 | 0.86 | SMN1; SMN2 (0.49) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL10144064 | 0.84 | CTSS (0.57) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL13934290 | 0.83 | CTSK (0.53) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL13921047 | 0.82 | CTSK (0.41) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL13956771 | 0.81 | CTSK (0.55) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2721327 | 0.81 | CTSK (0.55) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL30064534 | 0.81 | CTSK (0.45) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL16383328 | 0.81 | CTSK (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382193-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150315129-A1 | PROCESSES FOR FORMING AMIDE BONDS AND COMPOSITIONS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-8921599-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2014-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315129-A1 | PROCESSES FOR FORMING AMIDE BONDS AND COMPOSITIONS RELATED THERETO | TMT1A, LPO, GSTO1 | CYP1A2 1938/4885CYP2C9 1394/4885CYP2C19 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.